Aurobindo Pharma, at its board meeting today, has allotted 4 lakh equity shares and equal number of warrants to its promoters at Rs 226 per share/warrant.
The allotment is part of a series of preferential allotments that the company proposes to effect before April 15. At an extraordinary general meeting held on January 15, 2002, it had proposed to issue 55 lakh equity shares/warrants on preferential basis.
For the proposed issue, the company has received commitment from Templeton Emerging Markets to pick up 1 million equity shares and equal number of warrants. However, the company is yet to receive subscription from Templeton.
Even the promoters had committed to subscribe 1 million equity shares and equal number of warrants, of which they subscribed 4 lakh shares and warrants today.
The company intends to allot another 15 lakh equity shares/warrants to other investors.
Meanwhile, A J Kamath, who has stepped down from the company's directorship yesterday to provide a room for the appointment of independent external directors under corporate governance code, will soon assume the responsibility as group financial advisor.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
